Press Releases2017-09-13T20:17:34+00:00

Press Releases

Novartis’ Gilenya, Sanofi’s Aubagio, Biogen’s Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement

Although overall switch share for Roche’s Ocrevus is hampered by low treatment and switch rates for primary progressive multiple sclerosis, European neurologists vastly underestimate the dominance of the brand among such treated patients as revealed in the new audit by Spherix Global Insights

August 13, 2019|

US Nephrologists Are Optimistic About the Potential for Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) for the Treatment of Renal Anemia

According to Spherix Global Insights, nephrologists have high expectations that this novel class of oral agents may offer a safer way to treat renal anemia compared to erythropoietin stimulating agents (ESAs) such as Amgen’s Epogen and Aranesp  EXTON, Pa., August 1, 2019 / PRNewswire/ – In the latest report included in the RealTime Dynamix: Renal Anemia service, which represents the 16th consecutive wave, Spherix Global Insights surveyed 200 US nephrologists about the latest trends and perceptions related to renal anemia in the dialysis and non-dialysis settings. In addition to tracking the evolution of the ESA market and the rising [...]

August 1, 2019|

Robust Use of Janssen’s Tremfya and Positive Early Launch Metrics for AbbVie’s Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights

The US psoriasis landscape has come a long way since the first introduction of an alternate mechanism of action agent in a previously TNF-dominant market; IL-23 inhibitors are now in the spotlight  EXTON, Pa., July 25, 2019 /PRNewswire/ — Spherix began tracking the US psoriasis market through its RealTime Dynamix™: Psoriasis (US) service in early 2016, just one year following the launch of Novartis’ Cosentyx. The 2015 FDA approval of the first IL-17 inhibitor to enter the field ushered in an era of unprecedented efficacy for the management of psoriasis. With Eli Lilly’s Taltz and Ortho Dermatologics’ Siliq launching shortly [...]

July 25, 2019|

Launch of AbbVie’s Upadacitinib Expected to Cause a Stir in the US Rheumatoid Arthritis Market, According to Spherix Global Insights

As the user base of Regeneron’s Kevzara and Eli Lilly’s Olumiant continue to expand, US rheumatologists gear up for AbbVie’s JAK inhibitor to enter the market – with Pfizer’s Xeljanz most at risk for displacement Download Report Overview EXTON, Pa., July 18, 2019 /PRNewswire/ — The latest report included in Spherix’s RealTime Dynamix™ Rheumatoid Arthritis (US) independent service comprises the responses of 101 US rheumatologists and captures the impact of new product launches and market events on prescribing behavior and product perceptions. In the US rheumatoid arthritis (RA) market, it is clear that TNF inhibitors have historically dominated, [...]

July 19, 2019|

Eli Lilly’s Emgality is Perceived as Increasingly Competitive with Amgen/Novartis’ Aimovig and Teva’s Ajovy in the US Migraine Prevention Market, as the Anti-CGRP Brand Pulls Ahead on Payer Approval Ease and Overall Prescriber Satisfaction

Assuming positive regulatory outcomes for the preventive treatment of migraine, Biohaven Pharmaceuticals’ rimegepant and Allergan’s atogepant will quickly erode injectable anti-CGRP therapy share, resulting in a dominant position within the class, according to the 4th wave of Spherix Global Insights’ report series Download Report Overview EXTON, Pa., July 2, 2019 ― US neurologists and migraine specialists typically report few clinically relevant points of differentiation between the three brands in the new class of anti-calcitonin gene-related peptide (CGRP) therapies.  However, data highlighted in the recent Q2 wave of Spherix’s ongoing quarterly RealTime Dynamix™: Migraine Prevention (US) report series reveal several potential [...]

July 2, 2019|